Indivior Raises FY26 EBITDA Outlook to $620M-$660M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy INDV?
Consensus $1.16B. Raises FY26 adjusted EBITDA view to $620M-$660M from $535M-$575M. Backs FY26 operating expenses view $430M-$450M. "Strong SUBLOCADE performance in the first quarter led us to raise our 2026 financial guidance," said Ryan Preblick, Chief Financial Officer. "We now expect 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of our guidance ranges. We strengthened our financial position with the completion of a $500 million convertible senior notes offering and returned capital to our shareholders through the opportunistic repurchase of $125 million in shares during the quarter. We are committed to creating long-term shareholder value as we advance the Indivior Action Agenda."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.540
Low
36.00
Averages
43.75
High
50.00
Current: 36.540
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Claret Asset Management Acquires Indivior Shares Worth $23.36 Million
- New Investment Position: Claret Asset Management established a new position in Indivior during Q1 2026 by acquiring 707,267 shares valued at $23.36 million, indicating strong confidence in the company's growth potential.
- Holding Value Fluctuation: By the end of the quarter, Claret's holding in Indivior was valued at $21.56 million, reflecting market price changes and adjustments in asset allocation post-acquisition, thereby enhancing portfolio diversity.
- Significant Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, with Sublocade sales surging 32% to $232 million, demonstrating robust market demand for opioid dependence treatments.
- Strategic Buybacks: Indivior repurchased approximately 4 million shares for $125 million during the quarter and announced a $175 million accelerated share repurchase agreement with Barclays, reflecting confidence in its stock price and future growth expectations.
See More
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
Indivior Releases Survey Results on Medication Use in Correctional Facilities
- Survey Overview: Indivior's survey reveals that 88% of jail staff and 87% of prison personnel believe that long-acting injectable buprenorphine can effectively reduce medication for opioid use disorder (MOUD) diversion, indicating its potential in correctional settings.
- Implementation Barriers Identified: The survey also highlights structural barriers to effective MOUD program implementation, including inadequate medical and custody staffing, limited coordination between health services and custody, and operational challenges related to medication administration and monitoring, which hinder effective treatment delivery.
- Policy Recommendations: The findings underscore the need for policies and funding strategies to strengthen staffing capacity, enhance care coordination, and ensure sustainable MOUD delivery during incarceration and throughout reentry into the community, thereby supporting long-term recovery.
- Industry Impact: Indivior executives emphasize that simplified treatment models can improve patient access while enhancing institutional operational efficiency, reinforcing the significance of long-acting injectable buprenorphine as a viable implementation strategy.
See More
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
Claret Asset Management Acquires Indivior Shares Worth $23.36 Million
- New Investment Position: Claret Asset Management established a new position in Indivior during Q1 2026 by acquiring 707,267 shares valued at $23.36 million, indicating strong confidence in the company's growth potential.
- Holding Value Fluctuation: By the end of the quarter, Claret's holding in Indivior was valued at $21.56 million, reflecting market price changes and adjustments in asset allocation post-acquisition, thereby enhancing portfolio diversity.
- Significant Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, with Sublocade sales surging 32% to $232 million, demonstrating robust market demand for opioid dependence treatments.
- Strategic Buybacks: Indivior repurchased approximately 4 million shares for $125 million during the quarter and announced a $175 million accelerated share repurchase agreement with Barclays, reflecting confidence in its stock price and future growth expectations.
See More
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
Indivior Releases Survey Results on Medication Use in Correctional Facilities
- Survey Overview: Indivior's survey reveals that 88% of jail staff and 87% of prison personnel believe that long-acting injectable buprenorphine can effectively reduce medication for opioid use disorder (MOUD) diversion, indicating its potential in correctional settings.
- Implementation Barriers Identified: The survey also highlights structural barriers to effective MOUD program implementation, including inadequate medical and custody staffing, limited coordination between health services and custody, and operational challenges related to medication administration and monitoring, which hinder effective treatment delivery.
- Policy Recommendations: The findings underscore the need for policies and funding strategies to strengthen staffing capacity, enhance care coordination, and ensure sustainable MOUD delivery during incarceration and throughout reentry into the community, thereby supporting long-term recovery.
- Industry Impact: Indivior executives emphasize that simplified treatment models can improve patient access while enhancing institutional operational efficiency, reinforcing the significance of long-acting injectable buprenorphine as a viable implementation strategy.
See More
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
